Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

December 31, 2026

Conditions
ColitisIBD (Inflammatory Bowel Disease)Probiotic Intervention
Interventions
DRUG

Probiotics 6600

"As the core commensal bacteria of human body, probiotic 6600 has a unique ability to synthesize adhesins and exopolysaccharides. The intestinal protective effect is mediated by the following mechanisms: (1) regulation of Treg/Th17 balance by producing short-chain fatty acids (SCFAs); (2) activation of TLR2/MyD88 pathway inhibits NF-κB inflammatory cascade; (3) Upregulation of zonula occludens-1 enhances intestinal barrier function. Notably, this strain specifically metabolized arabinoxylan to produce the anti-inflammatory metabolite indole lactate, which has important therapeutic value in the colitis microenvironment.~Probiotic 6600 capsules are enteric capsules (containing probiotic 6600 10\^11 CFU/ capsule), taken orally twice a day (after meals in the morning and evening), one capsule each time, and taken with warm water. The drug was stored at 2-8℃."

DRUG

Placebo

The placebo capsules were also enteric-coated capsules, and were taken orally twice a day (morning and evening after meals), one capsule each time, with warm water.

Trial Locations (1)

Unknown

RECRUITING

Changhai Hospital, Shanghai

All Listed Sponsors
lead

Changhai Hospital

OTHER